COMMUNIQUÉS West-GlobeNewswire

Mithra updates on cash position
06/02/2024
Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early March Mithra is actively engaging with stakeholders Mithra will present its results for [...]
Mithra updates on cash position
06/02/2024
Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early March Mithra is actively engaging with stakeholders Mithra will present its results for [...]
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
06/02/2024
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and [...]
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
05/02/2024
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas Pelabresib recently [...]
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to March 3, 2024
05/02/2024
MIAMI, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that on February 1, 2024, its sponsor, [...]
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/02/2024
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to [...]
Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer
05/02/2024
Pfeil takes on expanded responsibilities while Globus fuels its next phase of growth AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today [...]
SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
05/02/2024
SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report [...]
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
05/02/2024
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced [...]
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
05/02/2024
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/02/2024
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
05/02/2024
GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
05/02/2024
GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected in first half of 2024 NOVATO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- [...]
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
05/02/2024
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to [...]
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
05/02/2024
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David [...]
IBA – Transparency Notification
05/02/2024
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 5, 2024 18:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA - PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE
05/02/2024
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 5 février 2024, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
Interim report for the first half of 2023/24 – Correction
05/02/2024
ANNOUNCEMENT NO. 250 5 February 2024 Interim report for the first half of 2023/24 – Correction In connection with the previously published interim report for the first half of 2023/24 (announcement no. 249), there were [...]
Immix Biopharma Announces Proposed Public Offering of Common Stock
05/02/2024
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it [...]

Pages